Literature DB >> 22147897

Comparative incidence of a first thrombotic event in purely obstetric antiphospholipid syndrome with pregnancy loss: the NOH-APS observational study.

Jean-Christophe Gris1, Sylvie Bouvier, Nicolas Molinari, Jean-Philippe Galanaud, Eva Cochery-Nouvellon, Erik Mercier, Pascale Fabbro-Peray, Jean-Pierre Balducchi, Pierre Marès, Isabelle Quéré, Michel Dauzat.   

Abstract

The incidence of thrombosis in the purely obstetric form of antiphospholipid syndrome is uncertain. We performed a 10-year observational study of 1592 nonthrombotic women who had experienced 3 consecutive spontaneous abortions before the 10th week of gestation or 1 fetal death at or beyond the 10th week of gestation. We compared the frequencies of thrombotic events among women positive for antiphospholipid Abs (n = 517), women carrying the F5 6025 or F2 rs1799963 polymorphism (n = 279), and women with negative thrombophilia screening results (n = 796). The annual rates of deep vein thrombosis (1.46%; range, 1.15%-1.82%), pulmonary embolism (0.43%; range, 0.26%-0.66%), superficial vein thrombosis (0.44%; range, 0.28%-0.68%), and cerebrovascular events (0.32%; range, 0.18%-0.53%) were significantly higher in aPLAbs women than in the other groups despite low-dose aspirin primary prophylaxis. Women carrying 1 of the 2 polymorphisms did not experience more thrombotic events than women who screened negative for thrombophilia. Lupus anticoagulant was a risk factor for unprovoked proximal and distal deep and superficial vein thrombosis and women in the upper quartile of lupus anticoagulant activity had the highest risk. Despite data suggesting that aPLAbs may induce pregnancy loss through nonthrombotic mechanisms, women with purely obstetric antiphospholipid syndrome are at risk for thrombotic complications.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22147897     DOI: 10.1182/blood-2011-09-381913

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  21 in total

Review 1.  Recurrent miscarriage, antiphospholipid antibodies and the risk of thromboembolic disease.

Authors:  M Ángeles Martínez-Zamora; Ricard Cervera; Juan Balasch
Journal:  Clin Rev Allergy Immunol       Date:  2012-12       Impact factor: 8.667

2.  A high-risk laboratory profile of antiphospholipid antibodies and thrombosis is associated with a large number of extra-criteria manifestations in obstetric antiphospholipid syndrome.

Authors:  Sebastián Udry; José Omar Latino; Cristina Belizna; Silvia Perés Wingeyer; Diego Santiago Fernández Romero; Gabriela de Larrañaga
Journal:  Immunol Res       Date:  2019-12       Impact factor: 2.829

3.  Obstetric antiphospholipid syndrome and long term arterial thrombosis risk.

Authors:  Genady Drozdinsky; Eran Hadar; Anat Shmueli; Rinat Gabbay-Benziv; Shachaf Shiber
Journal:  J Thromb Thrombolysis       Date:  2017-10       Impact factor: 2.300

4.  Diffusion tensor imaging in patients with obstetric antiphospholipid syndrome without neuropsychiatric symptoms.

Authors:  Fabricio R Pereira; Francesco Macri; Marcel P Jackowski; William J Kostis; Jean-Christophe Gris; Jean-Paul Beregi; Choukri Mekkaoui
Journal:  Eur Radiol       Date:  2015-07-23       Impact factor: 5.315

Review 5.  Additional Treatments for High-Risk Obstetric Antiphospholipid Syndrome: a Comprehensive Review.

Authors:  Amelia Ruffatti; Ariela Hoxha; Maria Favaro; Marta Tonello; Anna Colpo; Umberto Cucchini; Alessandra Banzato; Vittorio Pengo
Journal:  Clin Rev Allergy Immunol       Date:  2017-08       Impact factor: 8.667

6.  Discontinuation of anticoagulation or antiaggregation treatment may be safe in patients with primary antiphospholipid syndrome when antiphospholipid antibodies became persistently negative.

Authors:  Emmanuel Coloma Bazán; Carolina Donate López; Pedro Moreno Lozano; Ricard Cervera; Gerard Espinosa
Journal:  Immunol Res       Date:  2013-07       Impact factor: 2.829

Review 7.  Primary Thrombosis Prophylaxis in Persistently Antiphospholipid Antibody-Positive Individuals: Where Do We Stand in 2018?

Authors:  Yu Zuo; Medha Barbhaiya; Doruk Erkan
Journal:  Curr Rheumatol Rep       Date:  2018-09-10       Impact factor: 4.592

8.  Antiphospholipid antibody profile-based outcome of purely vascular and purely obstetric antiphospholipid syndrome.

Authors:  Amihai Rottenstreich; Ariela Arad; Hadas Terespolsky; Uriel Elchalal; Hagai Amsalm; Batia Roth; Yosef Kalish
Journal:  J Thromb Thrombolysis       Date:  2018-08       Impact factor: 2.300

9.  Clinical characteristics and prognosis of patients with isolated thrombotic vs. obstetric antiphospholipid syndrome: a prospective cohort study.

Authors:  Hui Jiang; Chu-Han Wang; Nan Jiang; Jing Li; Chan-Yuan Wu; Qian Wang; Meng-Tao Li; Xin-Ping Tian; Jiu-Liang Zhao; Yan Zhao; Xiao-Feng Zeng
Journal:  Arthritis Res Ther       Date:  2021-05-08       Impact factor: 5.156

10.  Factors associated with first thrombosis in patients presenting with obstetric antiphospholipid syndrome (APS) in the APS Alliance for Clinical Trials and International Networking Clinical Database and Repository: a retrospective study.

Authors:  G R de Jesús; S Sciascia; D Andrade; M Barbhaiya; M Tektonidou; A Banzato; V Pengo; L Ji; P L Meroni; A Ugarte; H Cohen; D W Branch; L Andreoli; H M Belmont; P R Fortin; M Petri; E Rodriguez; R Cervera; J S Knight; T Atsumi; R Willis; I S Nascimento; R Rosa; D Erkan; R A Levy
Journal:  BJOG       Date:  2018-10-24       Impact factor: 6.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.